Anti-LAV/HTLV-III antibodies in groups of individuals at high risk for infection in Italy. NLM AIDSLINE Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Anti-LAV/HTLV-III antibodies in groups of individuals at high risk for infection in Italy.

Ric Clin Lab. 1985 Oct-Dec;15(4):357-64. Unique Identifier : AIDSLINE MED/86207695
Zanetti AR; Ferroni P; Colombo M; Cargnel A; Mari D; Zehender G; Rumi MG; Gringeri A; Ammassari M; Mannucci PM

Abstract: We have studied anti-LAV/HTLV-III antibody prevalence in individuals at high risk for infection, such as intravenous drug addicts, hemophiliacs and homosexual men. Among intravenous drug addicts, LAV/HTLV-III infection was first recognized in 1981 and positive serum reactions for anti-LAV/HTLV-III antibody rose in successive years to 53%. Anti-LAV/HTLV-III antibody prevalence was 13.5% in the group of homosexual men, while in hemophiliacs treated with commercial concentrates it was 37% in 1984 and had increased to 45% in 1985. There was a significant correlation between antibody status and concentrate consumption in these patients. Results of studies of anti-LAV/HTLV-III antibody patterns with the Western blot technique suggest that antibodies against core proteins (mainly p25 and p18) and the envelope protein gp40 are always present in asymptomatic individuals and in patients with the lymphadenopathy syndrome, but usually not in patients with full-blown AIDS. These last patients have typical positive reactions only against the envelope proteins gp110 and gp40.
Keywords: Acquired Immunodeficiency Syndrome/*DIAGNOSIS/IMMUNOLOGY Antibodies, Viral/*ANALYSIS Electrophoresis, Polyacrylamide Gel Female Hemophilia/IMMUNOLOGY Homosexuality Human Immunoenzyme Techniques Male Sex Factors Substance Dependence/IMMUNOLOGY Support, Non-U.S. Gov't Viral Core Proteins/IMMUNOLOGY JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDdiagnosis/immunologyantibodies,viral/KWDanalysiselectrophoresis,polyacrylamidegelfemalehemophilia/immunologyhomosexualityhumanimmunoenzymetechniquesmalesexfactorssubstancedependence/immunologysupport,non-uKWDsKWDgov'tviralcoreproteins/immunologyjournalarticle
860830
M8680268

Copyright © 1986 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .